NCT07121933

Brief Summary

This study is to see if applying pre-treatment with the Erchonia® PPL blue laser therapy, followed sequentially with the standard Erchonia red laser therapy can help reduce nociceptive musculoskeletal pain

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 12, 2025

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 14, 2025

Completed
6 days until next milestone

Study Start

First participant enrolled

August 20, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 26, 2026

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 28, 2026

Completed
2 months until next milestone

Results Posted

Study results publicly available

June 4, 2026

Completed
Last Updated

June 4, 2026

Status Verified

May 1, 2026

Enrollment Period

7 months

First QC Date

August 12, 2025

Results QC Date

May 8, 2026

Last Update Submit

May 8, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage of Subjects With 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS)

    The Visual Analog Scale (VAS) from one day, baseline to endpoint measurement (following 13-minute treatment administration) is calculated for each subject. Individual subject success is defined as a 30% or greater change in VAS pain scores across the evaluation period. A negative (-) percent change indicates a decrease in pain level and is positive for individual subject success. A positive (+) percent change indicates an increase in pain level and is negative for individual subject success. Overall study success criteria is defined as at least 65%±5% (percentage of subjects) meeting the study individual success criteria.

    Day 1

Study Arms (1)

Erchonia® PPL

EXPERIMENTAL
Device: Erchonia® PPL blue laser therapy, followed sequentially with the standard Erchonia red laser therapy

Interventions

450 nanometers (nm) blue dual-diode laser application followed by 640nm red laser application

Erchonia® PPL

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older
  • Primary language is English
  • Subject presents with with one or more of:
  • chronic neck pain on the right side of the neck and/or the left side of the neck and/or the back of the neck; and/or
  • chronic shoulder pain on the right shoulder and/or the left shoulder.
  • Subject is diagnosed with of one or more of the following:
  • Osteoarthritis: Degenerative Joint Disorder (DJD)
  • Chronic Muscle Spasms
  • Cervical and Thoracic Spine Sprain Strain
  • Pain is chronic, having persisted for longer than the past 30 days
  • Self-reported Pain rating on the 0-100 Visual Analog Scale (VAS) of 50 or greater.
  • Willing and able to refrain from consuming any over-the-counter and/or prescription medication(s) and/or herbal supplements intended for the relief of pain and/or inflammation, including muscle relaxants throughout the course of study participation.
  • Willing and able to refrain from engaging in any non-study procedure therapies throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy and hot or cold packs, as well as alternative therapies such as chiropractic care and acupuncture

You may not qualify if:

  • Presenting primary pain is located outside or in addition to the region of the neck (right side/left side/back) or the shoulder (right and/or left side)
  • Etiology of neck/shoulder pain cannot be definitively diagnosed; or has bene diagnosed as being in whole or in part other than that of osteoarthritis, chronic muscle spasms or cervical and thoracic spine sprain strain; or other potentially contributing etiologies cannot be satisfactorily ruled out
  • Pain is acute: symptoms prevailed for fewer than each of the prior 30 days
  • Current active chronic pain disease: such as chronic fatigue syndrome and fibromyalgia
  • Use of analgesics or muscle relaxants within 7 days prior to study procedure administration
  • Use of systemic corticosteroid therapy (inhaled and topical corticosteroids permitted), narcotics or Botulinum toxin (Botox®) injection in the neck / shoulder region within 30 days prior to study procedure administration
  • Active cancer or treatment for cancer within the last 6 months
  • Unstable cardiac disease, such as recent cardiac arrhythmia, congestive heart failure or myocardial infarction
  • Prior surgery to the neck/shoulder region
  • Known herniated disc injury
  • Active infection, would or other external trauma to the areas to be treated with the laser
  • Medical, physical, or other contraindications for or sensitivity to light therapy
  • Serious known mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years
  • Pregnant or breast feeding
  • Participation in a research study within the past 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Laser Chiropractic

West Covina, California, 91790, United States

Location

MeSH Terms

Conditions

Musculoskeletal Pain

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Travis Sammons
Organization
Erchonia Corp

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 12, 2025

First Posted

August 14, 2025

Study Start

August 20, 2025

Primary Completion

March 26, 2026

Study Completion

March 28, 2026

Last Updated

June 4, 2026

Results First Posted

June 4, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations